Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Reports First Quarter 2020 Financial Results
Total Revenue Increases 43% Year-over-Year Continued Progress on Integration of Parcus Medical and Arthrosurface Acquisitions Withdrawing Full Year 2020 Financial Guidance Well Positioned to Manage through COVID-19 Pandemic BEDFORD, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.
View HTML
Toggle Summary Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer
Seasoned industry executive with experience leading global joint preservation and restoration businesses BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 27, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its
View HTML
Toggle Summary Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 23, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2020 financial results after the close of the market on Thursday, May 7, 2020 and hold its investor conference call on the same day, Thursday,
View HTML
Toggle Summary Anika Takes Actions to Strengthen Liquidity in Light of COVID-19
BEDFORD, Mass. , April 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (“HA”) technology platform , today provided an update on actions it is
View HTML
Toggle Summary Anika Appoints David Colleran as General Counsel
Seasoned executive brings extensive experience leading corporate legal and governance teams BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid
View HTML
Toggle Summary Anika Reports Fourth Quarter and Full Year 2019 Financial Results
Total Revenue Increases 10% Year-over-Year for the Fourth Quarter Completes Acquisitions of Parcus Medical and Arthrosurface Company Expects Total Revenue Growth in the 40% to 44% Range for Full Year 2020 BEDFORD, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) --   Anika Therapeutics, Inc.
View HTML
Toggle Summary Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO
BEDFORD, Mass. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard , a member of the Company’s Board of Directors since August 2018 , has been named interim Chief Executive Officer, effective immediately, while the Board continues
View HTML
Toggle Summary CORRECTING and REPLACING Anika to Issue Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights on Thursday, February 20
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 6, 2020-- First paragraph, first sentence should read: Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after the close of the market on Thursday, February 20, 2020
View HTML
Toggle Summary Anika Therapeutics Closes Acquisition of Arthrosurface
Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline BEDFORD, Mass. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.  (NASDAQ: ANIK), a global, integrated joint preservation
View HTML
Toggle Summary Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer
BEDFORD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. He was 62.
View HTML